Washington, D.C. Partner David Rosen was quoted in an Inside Health Reform article on July 17, 2013 titled, “FDA Legal Action Holds N.J. Compounder to Manufacturing Standards.” The article discusses a recent consent decree of permanent injunction against a drug compounder that FDA previously flagged mandates the pharmacy follow drug manufacturer standards. Mr. Rosen was quoted saying, “They’re holding them to drug manufacturer-style GMPs.” He also noted that drug companies involved in consent decrees sometimes enter a plan to rehab some of their products, whether it be active pharmaceutical ingredients or ingredients in process, but this must be approved by FDA and there is often a bond to ensure it is carried out.
People
Related News
April 13, 2026
In the News
Increase in Demand and Firm Growth Led Foley to Large Leaps in Revenue and PEP in a 'Year When It All Came Together'
Foley & Lardner LLP saw double-digit increases and all-time highs across all financial metrics in 2025 as noted in The American Lawyer article, “Foley Grows Revenue by Nearly 14%, PEP by 27%, in a 'Year When It All Came Together'.”
April 10, 2026
In the News
Foley's Texas Media Roundtable Highlighted for Insights on Today's Energy Transformations
Foley & Lardner LLP is featured across media for the firm’s recent roundtable discussion on energy trends related to grid reliability, data centers, and capital investments.
April 10, 2026
In the News
Deanna Reitman and Glenn Reitman Highlighted Across Media for Foley Arrival
Foley & Lardner LLP partners Deanna Reitman and Glenn Reitman attracted widespread media coverage for their recent arrival to the firm’s Houston office.